Cargando…
Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy (DMD) is a fatal X-linked disorder with a birth prevalence of 19.8:100,000 males worldwide. Elevated concentration of the muscle enzyme creatine kinase-MM (CK-MM) allows for presymptomatic screening of newborns using Dried Blood Spots (DBS). We evaluated imprecision and c...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883886/ https://www.ncbi.nlm.nih.gov/pubmed/35225934 http://dx.doi.org/10.3390/ijns8010012 |
_version_ | 1784660034521661440 |
---|---|
author | Migliore, Brooke A. Zhou, Linran Duparc, Martin Robles, Veronica R. Rehder, Catherine W. Peay, Holly L. Kucera, Katerina S. |
author_facet | Migliore, Brooke A. Zhou, Linran Duparc, Martin Robles, Veronica R. Rehder, Catherine W. Peay, Holly L. Kucera, Katerina S. |
author_sort | Migliore, Brooke A. |
collection | PubMed |
description | Duchenne Muscular Dystrophy (DMD) is a fatal X-linked disorder with a birth prevalence of 19.8:100,000 males worldwide. Elevated concentration of the muscle enzyme creatine kinase-MM (CK-MM) allows for presymptomatic screening of newborns using Dried Blood Spots (DBS). We evaluated imprecision and carryover of the FDA-approved PerkinElmer GSP Neonatal CK-MM kit over multiple runs, days, and operators, followed by quantification of CK-MM loss in stored newborn, contrived, and non-newborn patient DBS resulting from exposure to ambient versus low humidity (50-day trial), and high humidity and high temperature (8-day trial). Imprecision %CV was ≤14% for all verification comparisons and over 6 months of testing. On average, the mean CK-MM recovery after 50 days was >80% of initial concentration for all sample types stored in low humidity and <80% in ambient humidity. After 8 days of storage in high humidity and high temperature, the mean recovery for newborn samples was <80%. Verification results for the GSP Neonatal CK-MM assay were concordant with kit parameters and the assay performed consistently over 6 months. CK-MM degradation in ambient storage can be mitigated by reducing exposure to humidity. Assessment of DBS shipping and storage conditions is recommended prior to implementing DMD screening. |
format | Online Article Text |
id | pubmed-8883886 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88838862022-03-01 Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy Migliore, Brooke A. Zhou, Linran Duparc, Martin Robles, Veronica R. Rehder, Catherine W. Peay, Holly L. Kucera, Katerina S. Int J Neonatal Screen Article Duchenne Muscular Dystrophy (DMD) is a fatal X-linked disorder with a birth prevalence of 19.8:100,000 males worldwide. Elevated concentration of the muscle enzyme creatine kinase-MM (CK-MM) allows for presymptomatic screening of newborns using Dried Blood Spots (DBS). We evaluated imprecision and carryover of the FDA-approved PerkinElmer GSP Neonatal CK-MM kit over multiple runs, days, and operators, followed by quantification of CK-MM loss in stored newborn, contrived, and non-newborn patient DBS resulting from exposure to ambient versus low humidity (50-day trial), and high humidity and high temperature (8-day trial). Imprecision %CV was ≤14% for all verification comparisons and over 6 months of testing. On average, the mean CK-MM recovery after 50 days was >80% of initial concentration for all sample types stored in low humidity and <80% in ambient humidity. After 8 days of storage in high humidity and high temperature, the mean recovery for newborn samples was <80%. Verification results for the GSP Neonatal CK-MM assay were concordant with kit parameters and the assay performed consistently over 6 months. CK-MM degradation in ambient storage can be mitigated by reducing exposure to humidity. Assessment of DBS shipping and storage conditions is recommended prior to implementing DMD screening. MDPI 2022-01-28 /pmc/articles/PMC8883886/ /pubmed/35225934 http://dx.doi.org/10.3390/ijns8010012 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Migliore, Brooke A. Zhou, Linran Duparc, Martin Robles, Veronica R. Rehder, Catherine W. Peay, Holly L. Kucera, Katerina S. Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy |
title | Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy |
title_full | Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy |
title_fullStr | Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy |
title_full_unstemmed | Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy |
title_short | Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy |
title_sort | evaluation of the gsp creatine kinase-mm assay and assessment of ck-mm stability in newborn, patient, and contrived dried blood spots for newborn screening for duchenne muscular dystrophy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883886/ https://www.ncbi.nlm.nih.gov/pubmed/35225934 http://dx.doi.org/10.3390/ijns8010012 |
work_keys_str_mv | AT migliorebrookea evaluationofthegspcreatinekinasemmassayandassessmentofckmmstabilityinnewbornpatientandcontriveddriedbloodspotsfornewbornscreeningforduchennemusculardystrophy AT zhoulinran evaluationofthegspcreatinekinasemmassayandassessmentofckmmstabilityinnewbornpatientandcontriveddriedbloodspotsfornewbornscreeningforduchennemusculardystrophy AT duparcmartin evaluationofthegspcreatinekinasemmassayandassessmentofckmmstabilityinnewbornpatientandcontriveddriedbloodspotsfornewbornscreeningforduchennemusculardystrophy AT roblesveronicar evaluationofthegspcreatinekinasemmassayandassessmentofckmmstabilityinnewbornpatientandcontriveddriedbloodspotsfornewbornscreeningforduchennemusculardystrophy AT rehdercatherinew evaluationofthegspcreatinekinasemmassayandassessmentofckmmstabilityinnewbornpatientandcontriveddriedbloodspotsfornewbornscreeningforduchennemusculardystrophy AT peayhollyl evaluationofthegspcreatinekinasemmassayandassessmentofckmmstabilityinnewbornpatientandcontriveddriedbloodspotsfornewbornscreeningforduchennemusculardystrophy AT kucerakaterinas evaluationofthegspcreatinekinasemmassayandassessmentofckmmstabilityinnewbornpatientandcontriveddriedbloodspotsfornewbornscreeningforduchennemusculardystrophy |